Oxford Biomedica apresenta dados encorajadores da eficácia da ação do Prosavin® em doença de Parkinson

15 Nov 2006 - Veja em Medical News Today, em inglês.
(...) ProSavin is administered locally to the region of the brain called the striatum, delivering the genes for three enzymes that are required for the synthesis of dopamine. These genes are able to reprogram the cells that they enter, enabling these cells to manufacture and secrete dopamine. The treated brain region becomes a new endogenous source of dopamine, replacing the patient's own lost source of the neurotransmitter. Sustained expression of the genes is a key requirement for the product to be clinically successful. (...)